In myelodysplastic syndromes (MDS) increased chromosomal breaks point toward defects in DNA repair machinery including base excision repair (BER) pathway involved in handling of oxidative DNA damage. We investigated whether defects in this pathway can be found in MDS. Elevated levels of 8-oxoguanine (8-OG) were found in a significant proportion of MDS patients, indicating increased oxidative DNA damage or defective handling of oxidative load. In a distinct subgroup of patients, increased 8-OG content was associated with increased hOGG1 mRNA expression and activity. In some patients, increased numbers of abasic sites (AP sites) correlated with low levels of POLb. To further investigate the nature of this defect, we examined genetic lesions potentially explaining accumulation of 8-OG and AP sites. We genotyped a large cohort of MDS patients and found a correlation between increased oxidative damage and the presence of the hOGG1-Cys326 allele suggesting inadequate compensatory feedback. Overall, this hOGG1 variant was more frequent in MDS, particularly in advanced forms, as compared to controls. In summary, we demonstrated that BER dysfunction in some MDS patients may be responsible for the increased 8-OG incorporation and explains one aspect of the propensity to chromosomal breaks in MDS but other mechanisms may also be involved.
Introduction
Myelodysplastic syndromes (MDS) despite their heterogeneity have several unifying features including increased incidence in the elderly, chromosomal breaks 1, 2 and, in their secondary form, association with DNA damaging agents (chemotherapyrelated MDS). The acquired or germ line-encoded propensity to DNA damage may be the key pathogenetic feature that becomes apparent due to cumulative genotoxicity and increased repair need in advanced age. 3, 4 Theoretically, various defects may be involved that result in lesions in DNA integrity, random chromosomal breaks and subsequent selection of the most permissive dysplastic clone. Among possible lesions, DNA repair defects have often been implicated in MDS. [5] [6] [7] Initial DNA injury may result from oxidation, methylation, deamination or spontaneous loss of the DNA base itself. 8 These alterations may overwhelm DNA repair pathways, especially, if there is an intrinsic weakness of such mechanisms and/or increased demand for repairs. Free oxygen radicals have been suggested to cause mutations associated with human malignancies, including MDS. [9] [10] [11] [12] [13] In addition, oxidants can react with the sugar moiety of DNA, leading to the formation of secondary lesions (that is, abasic sites (AP sites) and single-strand breaks). The removal of oxidized bases is predominantly mediated by the base excision repair (BER) pathway 14, 15 and changes in gene expression or localization of the enzymes of BER could explain an increased propensity to chromosomal defects. [16] [17] [18] For example, overexpression of some BER-associated enzymes may lead to an enhanced resistance to clastogenic agents, hence, improving cellular protection from endogenous and exogenous mutagens. Conversely, overactivity of some elements of BER may contribute to mutagenesis. This is particularly evident for the majority of DNA glycosylases, whose imbalanced production with respect to the other major BER activities leads to sensitization of cells to DNA-damaging agents. Similarly, overactivity of DNA b-polymerase (POLb) may introduce mutagenic base analogs. 19, 20 In general, any functional disparity between BER enzymatic machinery and genotoxic stress may result in an excess of abasic sites (AP sites) and gapped DNA. 21 Such single-strand DNA interruptions resulting from incomplete repair might be converted into double-strand breaks during mitosis, giving rise to chromosome aberrations. 18 Moreover, lack of repair may yield to mechanical problems affecting chromosomal segregation, resulting in chromosomal aberrations. Finally, persistent oxidative damage can alter signaling cascades, induce or arrest transcription and cause replication errors. 13, 22 In addition, it can activate specific antioxidant in leukemic cells, rendering them resistant to chemotherapy.
7,8-Dihydro-8-oxoguanine (8-OG) incorporation is the most abundant oxidative DNA lesion; it is highly mutagenic because of its propensity to mispair with adenine thereby producing GC to TA transversions. 23, 24 A key component of BER pathway in human is hOGG1, which has both DNA glycosylase and AP lyse activities to excise 8-OG opposite cytosine. 25, 26 DNA glycosylase catalyzes the cleavage of the N-glycosidic bond between the damaged base and the sugar moiety, leaving an AP sites in DNA. The resulting 3 0 -blocking end is removed by the AP endonuclease and the gap is filled in by successive actions of other enzymes including POLb. 27 Subsequent steps include sealing of the remaining nick by the XRCC1-ligaseIII complex, thus, restoring DNA strand integrity.
Our study focuses on dysfunction of BER pathway in MDS as defined by inability to repair chemically modified nucleotides. As an initial screening for patients with defects of BER, we have selected incorporation of 8-OG into DNA, as this can serve as a marker for oxidative DNA damage. We hypothesized that increased 8-OG content in MDS may point toward lesions along BER pathway that could explain the increased propensity to DNA damage and ultimately chromosomal breaks. Consequently, in a cohort of MDS patients, we have applied a rational stepwise approach that included determination of 8-OG content, mRNA expression level and activity of hOGG1, expression level of POLb and quantification of AP sites. Furthermore, we searched for the presence of functional polymorphism in the hOGG1 gene and studied its functional consequences. The results of these assays were correlated with patients' clinical phenotype.
Materials and methods

Patients
Informed consent was obtained for sample collection from patients and controls according to the protocols approved by the Institutional Review Board of The Cleveland Clinic. MDS patients were classified according to the WHO classification. 28, 29 Mononuclear cells were isolated from whole blood and bone marrow by density centrifugation (Medatech Inc., VA, USA) and DNA was extracted using Genomic DNA Purification Kit (Gentra Systems Inc., MN, USA). In addition to the functional studies performed, a cohort of 146 Caucasian patients with MDS was used for genotyping studies. As a reference, a cohort of 350 Caucasian controls was used. 30 The mean age of cases and controls were 66 and 65 years with male/female ratio of 39:61 and 42:58, respectively.
Flow cytometry
The OxyFlow Research Kit (HemoGenix Inc., CO, USA) was used to evaluate oxidative DNA damage in whole blood. Briefly, prior to incubation with fluorescein isothiocyanate (FITC)-conjugated reagent, red blood cells were lysed and white cells fixed. After washing, the cells were permeabilized, washed again and equilibrated with the reagent wash buffer. Progenitor and stem cell isolation and RNA extraction CD34 þ cells were purified from bone marrow mononuclear cells either by sorting with anti-CD34 magnetic beads (Miltenyi Biotech Inc., Auburn, CA, USA) or by flow cytometric sorting (Beckman Coulter Epics Altra). The purity of these cells was confirmed by flow cytometry and ranged between 85 and 95%. Total RNA was extracted from cells using RNeasy Mini kit (Qiagen Inc., Valencia, CA, USA) and dissolved in diethylpyrocarbonate water. The purity of total RNA was confirmed by spectrophotometry using NanoDrop instrument (NanoDrop Technologies, Wilmington, DE, USA).
TaqMan gene expression assays cDNA was generated from 5 ml of total RNA by first strand cDNA synthesis using SuperScript III RT Kit (Invitrogen, Carlsbad, CA, USA). Gene expression of hOGG1 and POLb was studied in six leukemic cell lines (KG1, K562, TF1, UT7, HEL and HL60) and CD34 þ cells derived from 35 MDS patients and 8 healthy individuals. Briefly, 12.5 ml of 2Â TaqMan Universal Master Mix (PE ABI, Foster City, CA, USA) was used with 1.25 ml 20 Â TaqMan Gene Expression Mix (PE ABI) and 1 ml cDNA. In parallel, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene expression was analyzed by using the human GAPDH kit (PE ABI). Samples were run in triplicate on a 7500 Real-Time PCR system (PE ABI) at 95 1C for 10 min followed by 40 cycles of 15 s at 95 1C and of 60 s at 60 1C. The values obtained for the target gene expression were normalized to GAPDH and expressed in relation to the expression in control samples (fold change of controls). All values below 1 (reference) were replaced with the negative reciprocal value to correspond to lower expression as relative to the controls.
8-OG-specific lyase activity assay ]-dATP-labeled double-stranded oligonucleotide was incubated with 250 mg of proteins, at 37 1C for 60 min in a final volume of 100 ml containing 50 mM HEPES, pH 7.5, 50 mM KCl, 0.025% TRITON X-100 and 1 mg ml À1 bovine serum albumin. After phenol-chloroform-isoamyl extraction, DNA was ethanolprecipitated for 30 min at À20 1C with 90 mM sodium acetate, pH 5.2, followed by 5 min incubation with 0.1 M Putrescine pH 8.0. The resulting DNA fragments were separated by 12% bis/acrylamide gel with 7 M urea, and analyzed by PhosphorImage analysis on a Storm-840 imager using Image Quant v 4.2 software (Molecular Dynamics, Amersham Biosciences, Piscataway, NJ, USA). Calculation of the hOGG1 activity was carried out by quantification of the radioactivity in the cleaved 10-mer in relation to that of the 23-mer substrate (699 fmol).
Allelic discrimination assay
Allelic discrimination of hOGG1 Ser326Cys was performed using a TaqMan assay (PE ABI). The primers and probes were created using Assays-by-Design software (PE ABI). Briefly, the allele specific probes were labeled at their 5 0 termini with FAM or VIC fluorescent dyes. One fluorescent detector was a perfect match to the wild type (Ser326Ser) and the other was a perfect match to mutation (Cys326Cys). Minor groove binder was attached to the nonfluorescent quencher at the 3 0 terminus of the probe to facilitate melting. Each reaction contained 40 ng of genomic DNA, TaqMan Universal PCR Master Mix and SNP Genotyping Assay Mix (PE ABI) in a final volume of 25 ml. Realtime PCR and subsequent analysis were performed on the 7500 Real-Time PCR system (PE ABI) using the following conditions: initial pre-run at 60 1C for 1 min, followed by denaturation 95 1C for 10 min and then 40 cycles of amplification (95 1C denaturation for 15 s, 60 1C annealing/extension for 1 min). A substantial increase in VIC dye fluorescence only indicated homozygosity for allele 1, in FAM dye homozygosity for allele 2, both fluorescence signals heterozygosity for allele 1 and 2.
Quantification of AP sites
The level of AP sites in genomic DNA was estimated using the DNA damage quantification kit (BioVision, Mountain View, CA, USA). Briefly, after treating DNA containing AP sites (0.5 mg ml À1 ) with the Aldehyde Reactive Probe (ARP) reagent, AP sites were tagged with biotin residues and then quantified using an avidin-biotin assay followed by colorimetric detection. Each sample and standards were run in triplicate and the OD was measured at 650 nm within 1 h using a 96-well plate reader (Lab Systems Multiscan RC, Thermo Lab Systems, Franklin, MA, USA). A calibration curve obtained with standard ARP-DNA solutions served to determine the number of AP sites (per 10 6 bp) for each sample. In some patients with MDS, AP sites were evaluated after incubation with hOGG1 (Trevigen, Gaithersburg, MD, USA) at 37 1C for 60 min. Following hOGG1 treatment, the AP site protocol was followed (see above).
Statistical analysis
The genotypes and allele frequency were assessed for significance by w 2 -test. Alternatively, Student's t-test, Fisher's exact probability test and analysis of variance were used for all other analysis (JMP 6.0 Cary, NC, USA). Fisher's test was applied when the numbers in the contingency table were lesser than 5. Trend P-values of r0.05 were considered significant.
Results
Detection of DNA 8-OG in leukocytes of patients with MDS
8-OG can be detected using flow cytometry; following a fluorescent-binding reaction specific for 8-OG, the difference in the mean of relative fluorescence between subpopulations of granulocytes and lymphocytes reflects the amount of DNA incorporating 8-OG (Figures 1a-d) . When 8-OG incorporation was expressed as a geometric mean of 8-OG fluorescence ('average' fluorescence of log distribution within specific regions), increased levels of 8-OG were found in 67% of all MDS cases studied (N ¼ 24). Similarly, elevated 8-OG incorporation was also found when 8-OG fluorescence was compared not to internal controls (lymphocytes) as shown above but also to granulocytes of controls (N ¼ 9) (data not shown). For further analysis, we dichotomized patients by a stringent definition of increased 8-OG content (defined as Xmean þ 2 s.d. of controls) and identified 8 of 24 patients who fulfilled this criterion. Patients within this group were characterized by a more advanced stage of MDS (P ¼ 0.001), more profound cytopenias (neutropenia P ¼ 0.002, thrombocytopenia P ¼ 0.02), greater propensity for AML transformation (P ¼ 0.02) and a higher number of blasts in bone marrow (P ¼ 0.001) as compared to the remaining group of patients (pmean þ 2 s.d.). However, there was no correlation between the level of 8-OG and the presence of clonal karyotypic abnormalities, smoking habits or the hOGG1 Ser326Cys polymorphism (Figure 1e ). Of note is that no age difference was found between patient groups with high and low 8-OG content (mean ± s.d.; 64.75 ± 14.86 vs 69.87±13.16, respectively, P ¼ 0.39).
hOGG1 DNA repair gene expression and activity in patients with MDS We investigated the mRNA expression level of hOGG1 in cell lines and CD34 þ cells from 35 MDS patients and 8 controls. For proper analysis, to eliminate inter-individual variation of hOGG1 in healthy donors, mean ± s.d. mRNA expression of hOGG1 within controls was calculated and served as reference for the proper determination of relative expression levels (fold change of controls) and comparison within individual subgroups of MDS patients (Figure 2 ). For the purpose of this study, only cases with greater than or equal to/less than or equal to twofold expression level of controls were further investigated.
Based on hOGG1 expression, two distinct patterns were found allowing for subclassification of affected patients. While increased expression of hOGG1 was found in 37% of MDS patients (greater than or equal to twofold increase in level of controls), 20% of cases showed lower than normal hOGG1 mRNA expression (less than or equal to twofold decrease in level of controls). Among patients with upregulated hOGG1, 61% had notably elevated levels of hOGG1 (greater than or equal to threefold expression level of controls). Of note is that in two patients, a striking increase in expression (greater than or equal to eighteen-fold increase in level of controls) was observed. In contrast, 20% MDS patients with underexpression of hOGG1 mRNA, pointed toward an inherent lesion that required further investigation. Within this group, four patients were diagnosed with sAML and most of them were characterized by an increased number of blasts in their bone marrow (Po0.05) as compared to the remaining group. In addition, four leukemic cell lines also showed downmodulation of hOGG1.
We also correlated hOGG1 mRNA expression with the biochemical activity of this enzyme. In MDS patients, mean hOGG1 activity was increased on average 2.3-fold (22.26 ± 6.03 fmol in MDS vs 9.70±1.82 fmol in controls, Po0.0001). No significant correlation of 8-OG-specific lyase activity with gender was observed (females: 22.69±5.02 fmol; males 21.95 ± 6.90 fmol). In patient groups with elevated/decreased hOGG1 mRNA expression also increased/decreased 8-OGspecific lyase activity was detected. For example, in patients with greater than or equal to twofold (average of 6.9-fold) increase of hOGG1 expression, 8-OG-specific lyase activity was also increased (2.4-fold of controls). Similarly, the moderate reduction in enzyme activity was observed in cases with underexpression of hOGG1. Moreover, the lowest 8-OGspecific incision activity was detected in patients with more malignant forms of MDS.
POLb DNA repair gene expression
Changes in gene expression of hOGG1 could have diverse consequences on the downstream elements of the pathway, for example, POLb which is responsible for the synthesis and removal of a 5 0 -sugar phosphate residue by catalyzing b-elimination process. Most of the patients demonstrated POLb mRNA levels comparable to those measured in controls. Only 34% of patients demonstrated a distinct POLb mRNA expression pattern (greater than or equal to/less than or equal to twofold change of controls). Among these patients, we identified two subgroups: 7 of 35 patients (20%) exhibited lower and 5 of 35 patients with MDS (14%) higher expression level of POLb. Remarkably, most patients with overexpression of POLb were characterized by concordant overexpression of hOGG1 mRNA expression (greater than or equal to twofold change of controls, N ¼ 4). This finding points toward an overwhelming oxidative stress despite an adequate feedback response. The remaining patients with underexpression of POLb may harbor defective upstream elements of BER, including endonuclease.
Genetic determinants of hOGG1 BER insufficiency
We speculated that some of the differences in hOGG1 mRNA expression patterns could reflect feedback mechanisms resulting from the presence of genetic variants of DNA repair genes. For instance, a C/G genetic polymorphism of hOGG1 at position 1245 in exon 7 is present in Caucasian population at a frequency of 27%. 30 This polymorphism encodes a serine to cysteine amino acid substitution in codon 326 of the corresponding protein, and is associated with increased 8-OG-specific lyase activity in the purified hOGG1-Ser326 protein compared to purified hOGG1-Cys326. 31 To examine whether there is association between the C/G SNP and hOGG1 response to oxidative stress at transcriptional level, cases with hOGG1 mRNA expression defined as greater than or equal to/less than or equal to twofold of controls were plotted against of the incidence of all hOGG1 genotypes. As a result, a significant trend was observed between hOGG1 genotypes and enzyme expression. Carriers of hOGG1-Cys326 exhibited higher than normal hOGG1 mRNA expression as compared with hOGG1-Ser326 (N ¼ 18, P ¼ 0.008). Both the homozygous (P ¼ 0.05) and the heterozygous (P ¼ 0.01) carriers were significantly different with respect to hOGG1 mRNA expression (Figure 3a) . This overexpression of hOGG1 likely compensated for the functional impairment due to Ser326Cys polymorphism, as we did not detect any differences in 8-OG-specific lyase activity, when patients were subdivided with respect to genotypes of hOGG1 (P ¼ 0.80, Figures 3b and c) . Neither the homozygous nor the heterozygous carriers were significantly different with respect to enzyme activity (21.08 ± 4.19 and 22.97 ± 10.50 fmol, respectively). Carriers of hOGG1-Ser326 showed a mean activity of 22.70 ± 4.03 fmol, whereas carriers of hOGG1-Cys326 had a mean activity of 21.94±7.34 fmol.
Prevalence of hOGG1 genotypes and risk for MDS
To determine whether the hOGG1-Cys326 allele contributed to an increased risk for MDS, we genotyped a larger cohort of MDS patients (N ¼ 146). The proportion of MDS patients with a polymorphic variant of hOGG1 in this group was higher than in the control group, with the difference in the distribution of genotypes reaching statistical significance (P ¼ 0.002; Figure 3d ). Significantly increased risk for MDS was observed for subjects both heterozygous (P ¼ 0.02, OR ¼ 1.7, 95% CI ¼ 1.1-2.5) and homozygous (P ¼ 0.05, OR ¼ 2.8, 95% CI ¼ 1-7.2) for the hOGG1 Ser326Cys polymorphism, a finding that was not affected by age or sex (67.10 ± 11.4, N ¼ 61 for hOGG1-Cys326, N ¼ 85 for hOGG1-Ser326). Because of the diversity within MDS, we stratified patients by clinical stages of the disease (advanced and low grade MDS), to investigate the potential associations between the hOGG1 genotypes and prognosis of disease. The gene-dose effect was observed in advanced MDS where 67% cases were found to be homozygous for the hOGG1-Cys326 polymorphism (OR ¼ 4.7, 95% CI ¼ 1.6-13, Po0.01; Figure 3d ). Moreover, within this group an association between the presence of hOGG1-Cys326 allele and increased frequency of chromosomal abnormalities (Po0.02) was found.
Quantification of AP sites in patients with MDS
In addition to base damage, reactive oxygen species (ROS) can also induce lesions by hydrogen abstraction of the deoxyribose, frequently producing oxidized AP sites and DNA strand breaks. Because it is believed that these oxidized bases are predominantly repaired through BER pathway, we investigated the levels of AP sites either in bone marrow or whole blood of MDS patients and correlated with gene expression of POLb and hOGG1 and 8-OG incorporation.
While increased incorporation of 8-OG (Xmean þ 2 s.d. of controls) resulted in an elevated number of AP sites (6.61±3.11 AP/10 6 bp), reduction of AP sites (5.10 ± 2.59 AP/10 6 bp) was observed in patients with low 8-OG content (pmean þ 2 s.d. of controls). As compared to normal controls (3.03 ± 2.74 AP/10 6 bp), patients in both groups had an elevated number of AP sites (P ¼ 0.02 and 0.13, respectively) (Figure 4a ). This relationship endured even after induction of AP sites by in vitro digestion with hOGG1; when AP sites were enumerated in patients with high 8-OG incorporation, they displayed a much higher number of AP sites (37.01 ± 15.76 AP/10 6 bp) as compared to controls (4.45±2.60 AP/10 6 bp, P ¼ 0.0001) or those with normal 8-OG content (24.91 ± 6.41 AP/10 6 bp, P ¼ 0.03) (Figure 4b) . Moreover, when AP sites were plotted against the 8-OG content, a positive association was observed (Po0.01, Figure 4c ). When we clustered the patients based on the expression levels of hOGG1 and/or POLb (greater than or equal to/less than or equal to twofold levels of expression in controls), we did not find any significance within these groups (Figure 4d) . However, the modest reduction of AP sites was seen with increasing expression of POLb (P ¼ 0.07), supporting our initial theory that defective upstream elements of the BER may be found in a subgroup of patients with MDS (Figure 4e ).
Discussion
Chromosomal instability due to acquired or constitutive insufficiency of the DNA repair machinery may explain the presence of chromosomal breaks in MDS. Lesions induced by endogenous and exogenous mutagens can either be fully repaired or lead to DNA defects, 17 ,18 with chromosomal Figure 3 Genotypic and allele frequency of the polymorphism at codon 326 and activity of hOGG1 variants in patients with myelodysplastic syndromes (MDS). Comparison between frequency of hOGG1 genotypes in MDS patients and hOGG1 mRNA expression levels (a), and 8-OGspecific lyase activity (b). Patients were divided according to mRNA expression level relative to controls (greater than or equal to/less than or equal to twofold change) and genetic polymorphism of hOGG1. All values below 1 (reference) were replaced with the negative reciprocal value to correspond to lower expression relative to controls. In all carriers of hOGG1-Cys326, hOGG1 was overexpressed as compared to hOGG1-Ser326 carriers, reaching statistical significance (C4G, P ¼ 0.01, G4G, P ¼ 0.05). aberrations representing the end result of likely diverse defects in various DNA repair pathways. The current study was designed as a rational stepwise approach to investigate whether defects in the repair of oxidative DNA damage can be identified either in all or in a distinct subgroup of MDS patients. As an initial step, we limited our investigation to patients most likely harboring such lesions based on a high content of 8-OG as a marker of ongoing/ unrepaired oxidative DNA stress. 32, 33 Indeed, we demonstrate that in a subset of MDS patients levels of 8-OG are elevated in myeloid cells, a result that points toward increased oxidative DNA damage that has either overwhelmed normal repair responses or is a reflection of an inadequate handling of normal oxidative load. Increased incorporation of 8-OG was observed when control granulocytes (healthy individuals) as well as patients' nonclonal lymphocytes were used as reference. Should clonal cells have acquired a defect in handling of oxidative damage, they would show increased levels as compared to lymphocytes, thus, constituting the most stringent internal control. Previous studies utilized a similar approach; increased 8-OG content was detected in other malignancies including lung, renal, breast and colorectal carcinomas when corresponding normal tissues were used as a reference. 9, 13 So far, there are only a few reports in which urinary 8-OG concentration in patients with hematological malignancies were studied 34 and our study represents the first application of flow cytometric assay for quantification of 8-OG adducts to hematopoietic cells.
One of the possible mechanisms for the increased 8-OG content may be related to an insufficient induction of hOGG1 in response to oxidative stress and/or reduced activity of the enzyme; low hOGG1 mRNA expression and reduced activity have been previously shown to represent a mutator phenotype. [35] [36] [37] As expected, low mRNA expression levels of hOGG1 and reduced 8-OG incision activity were found in patients with advanced MDS. Although the correlation of 8-OG levels with aggressive disease may indicate a secondary defect, it is also possible that an intrinsic BER defect may lead to a more rapid progression.
However, we also demonstrate that in some MDS patients, increased 8-OG content was associated with an increased hOGG1 expression and/or 8-OG-specific lyase activity. The increased mRNA level detected in those patients was likely a sign of enhanced DNA repair activity. Other factors include ageassociated changes in expression levels and subcellular localization of hOGG1. 38 We and many other investigators suggest that increased hOGG1 expression is a result of a feedback mechanisms likely triggered by an increased level of oxidative stress. 39 For instance, in patients with RARS, ferric iron accumulated in response to increased production of ROS species 12 could contribute to upregulation of hOGG1. In this study, we did not focus on ROS production, as this issue has been a topic of many studies showing that increased oxidative stress may be a pathophysiologic factor frequently present in MDS 11, 12, 34 . Correlation between various types of oxidative stress, including increased lipid peroxidation and nitrosylation and expression of various enzymes of DNA repair machinery are subject of an ongoing study. Nevertheless, our observations allow the conclusion that increased oxidative stress would further contribute to DNA damage in particular if the BER pathway is defective.
As POLb is positioned downstream of hOGG1 in the BER pathway, overexpression of this enzyme concordant to hOGG1 suggests activation of the entire pathway as an appropriate response to increased oxidative stress. Conversely, decreased POLb may denote that the defect is located downstream of hOGG1. Our results indicate that both constellations can be encountered among MDS patients. Previous studies suggest that alteration in POLb expression, an error-prone DNA synthesizing enzyme, could enhance both cell death and genetic changes associated with a malignant phenotype. 20 One of the cellular consequences of elevated levels of POLb may be increased incorporation of 8-OG in DNA.
When we investigated the numbers of AP sites in the context of hOGG1 expression level, we showed that low level of POLb was associated with an inability to complete the repair cycle and resulted in accumulation of AP sites. This finding supports the notion that hOGG1 was not a culprit in this group of patients. In contrast, for MDS patients in whom POLb was normal or increased, an appropriate response along the BER pathway was expected.
Consequently, we examined molecular mechanisms that could explain accumulation of 8-OG and AP sites. Increased expression of hOGG1 may be due to various pathophysiologic mechanisms, including polymorphic variants of BER enzymes and (as described above) increased oxidative stress. In this study, we investigated the presence of a dysfunctional hOGG1 polymorphism previously associated with a functional change in enzyme activity. 31 We demonstrate here a correlation between increased mRNA expression level of hOGG1 and the presence of the hOGG1-326Cys allele, suggesting inadequate compensatory feedback. However, globally we were not able to demonstrate correlation between decreased hOGG1 lyase activity and Ser326Cys polymorphism. This finding is likely due to the principle of the assay that utilizes extracts from cells as a source of hOGG1 activity. We have demonstrated that hOGG1 expression was upregulated in patients with this hOGG1-326Cys allele and likely compensates for decreased activity. Nevertheless, persistently elevated 8-OG content found in some patients may suggest that the upmodulation of hOGG1 may not always be adequate.
Based on the increased, potentially compensatory hOGG1 expression expected in patients with genetic variants of hOGG1 with decreased activity, 31 we genotyped a larger cohort of MDS patients and showed that the hOGG1 Ser326Cys SNP is more frequently encountered, particularly in those with advanced forms, as compared to controls. This finding provides further evidence that dysfunction of hOGG1 may constitute a risk factor for the development of MDS. Previously, association between hOGG1 Ser326Cys polymorphism and lung, oral, esophageal and prostate cancers but not stomach, colon or breast cancers was found, suggesting that covariate factors, including, for example, environmental influences and tissue location could play a role. 40 Except for the association of higher 8-OG incorporation with more advanced disease, individual subgroups of patients characterized by mRNA expression of hOGG1 and/or POLb and numbers of AP sites did not show distinct clinical features. While the propensity to increased oxidative DNA damage or dysfunction of BER pathway may be a part of the pathogenesis of MDS, the clinical phenotypes reflect and depend upon the biologic properties of the malignant clones. Their diversity is likely responsible for the variability of the clinical features further modified by multitude of external factors such as genetic background, age and comorbidities. Consequently, identification of distinct clinical features or stringent clinical correlation is unlikely and does not preclude the relevance of the observed molecular defects.
In summary, we have demonstrated that BER dysfunction may be responsible for the observed 8-OG incorporation seen in a subtype of MDS patients. It is likely that this mechanism explains one aspect of the propensity to the chromosomal breaks in MDS. Other mechanisms, alone or in addition to the observed BER dysfunction, may also be involved. Of note is that the clinical phenotype may be related to the biology of the dominant clonal defect that could result from various molecular lesions.
